Scilex Holding Company provided sales guidance for the fiscal year ended December 31, 2023. For the period, the company expects total product net sales were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.87 USD | +6.32% | +4.79% | -57.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.35% | 105M | |
+10.23% | 9.11B | |
-10.76% | 5.21B | |
+53.60% | 4.83B | |
+7.56% | 4.09B | |
-21.42% | 2.35B | |
+14.51% | 2.32B | |
+25.03% | 2.27B | |
-30.36% | 2.19B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023